Trial Profile
Evaluating the Effect of Aprepitant on Cyclophosphamide Pharmacokinetics.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Mar 2017
Price :
$35
*
At a glance
- Drugs Aprepitant (Primary) ; Cyclophosphamide; Doxorubicin
- Indications Chemotherapy-induced nausea and vomiting; Early breast cancer
- Focus Pharmacogenomic; Pharmacokinetics
- Acronyms NRR
- 12 Aug 2008 New trial record.